PTC Therapeutics (NASDAQ:PTCT) Director Stephanie Okey Sells 15,167 Shares of Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) Director Stephanie Okey sold 15,167 shares of PTC Therapeutics stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $70.00, for a total value of $1,061,690.00. Following the completion of the sale, the director directly owned 8,000 shares of the company’s stock, valued at $560,000. The trade was a 65.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Stephanie Okey also recently made the following trade(s):

• On Thursday, March 5th, Stephanie Okey sold 6,333 shares of PTC Therapeutics stock. The shares were sold at an average price of $63.38, for a total value of $401,385.54.

PTC Therapeutics Stock Up 1.2%

NASDAQ:PTCT traded up $0.79 on Friday, hitting $64.15. The stock had a trading volume of 264,250 shares, compared to its average volume of 1,275,732. The business’s 50-day simple moving average is $71.98 and its two-hundred day simple moving average is $69.65. The stock has a market cap of $5.31 billion, a price-to-earnings ratio of 8.29 and a beta of 0.51. PTC Therapeutics, Inc. has a 52-week low of $35.95 and a 52-week high of $87.50.

PTC Therapeutics (NASDAQ:PTCT) last issued its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.67) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($1.46). The business had revenue of $164.68 million during the quarter, compared to the consensus estimate of $281.45 million. PTC Therapeutics had a negative return on equity of 362.45% and a net margin of 39.44%.PTC Therapeutics’s revenue for the quarter was down 22.7% on a year-over-year basis. During the same quarter last year, the company earned ($0.85) EPS. As a group, equities research analysts anticipate that PTC Therapeutics, Inc. will post -4.52 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. UMB Bank n.a. purchased a new stake in PTC Therapeutics in the 4th quarter worth $26,000. Smartleaf Asset Management LLC boosted its stake in shares of PTC Therapeutics by 101.3% in the third quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 236 shares during the period. Optiver Holding B.V. grew its position in shares of PTC Therapeutics by 96.5% during the third quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 249 shares in the last quarter. Comerica Bank raised its stake in PTC Therapeutics by 868.5% during the 3rd quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 469 shares during the period. Finally, Salomon & Ludwin LLC bought a new stake in PTC Therapeutics during the 4th quarter valued at approximately $41,000.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of PTC Therapeutics in a research note on Friday, February 20th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of PTC Therapeutics in a report on Monday, December 29th. Wells Fargo & Company lowered their target price on PTC Therapeutics from $93.00 to $86.00 and set an “overweight” rating on the stock in a research report on Friday, February 20th. Wall Street Zen lowered PTC Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 21st. Finally, Royal Bank Of Canada reduced their price target on PTC Therapeutics from $87.00 to $82.00 and set a “sector perform” rating for the company in a research report on Friday, February 20th. Ten research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $82.79.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.